Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study.
10.1007/s11596-016-1567-x
- Author:
Yong-feng LI
1
;
Zhi-qiang LIU
1
;
Yu-shun ZHANG
1
;
Li-ming DONG
1
;
Chun-you WANG
1
;
Shan-miao GOU
1
;
He-shui WU
2
Author Information
1. Pancreatic Disease Institute, Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Pancreatic Disease Institute, Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. heshuiwu@163.com.
- Publication Type:Journal Article
- Keywords:
125I seed implantation;
locally advanced pancreatic cancer;
pain relief;
quality of life
- MeSH:
Adult;
Aged;
Drug-Eluting Stents;
adverse effects;
Female;
Humans;
Iodine Radioisotopes;
administration & dosage;
therapeutic use;
Male;
Middle Aged;
Pancreatic Neoplasms;
pathology;
radiotherapy;
Quality of Life;
Radiopharmaceuticals;
administration & dosage;
therapeutic use;
Survival Analysis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(2):205-210
- CountryChina
- Language:English
-
Abstract:
Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from (125)I seed implantation. This retrospective study included 224 patients with locally advanced pancreatic cancer, with 137 patients (61.2%) in the implantation (IP) group and 87 (38.9%) in the non-implantation (NIP) group. The survival status, complications and objective curative effects were compared between the groups. The average operative time in the IP group was significantly longer than that in the NIP group (243±51 vs. 214±77 min). The tumor response rates were 9.5% and 0 at the 2nd month after surgery in the IP and NIP groups, respectively (P<0.05). The IP group exhibited a trend toward pain relief at the 6th month after surgery. The global health status scores of the IP group were higher than those of the NIP group at the 3rd and 6th month after surgery. The median survival time in the IP group was significantly longer than that in the NIP group. In conclusion, patients with locally advanced pancreatic cancer can benefit from (125)I seed implantation in terms of local tumor control, survival time, pain relief and quality of life.
